Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer

H J Braam; J H Schellens; H Boot; J W van Sandick; C A Knibbe; D Boerma; B van Ramshorst

doi:10.1016/j.critrevonc.2015.04.004

Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer

Crit Rev Oncol Hematol. 2015 Sep;95(3):282-96. doi: 10.1016/j.critrevonc.2015.04.004. Epub 2015 Apr 17.

Authors

H J Braam¹, J H Schellens², H Boot³, J W van Sandick⁴, C A Knibbe⁵, D Boerma⁶, B van Ramshorst⁶

Affiliations

¹ Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands. Electronic address: H.Braam@antoniusziekenhuis.nl.
² Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
³ Division of Gastroenterology and Hepatology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁴ Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁵ Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands.
⁶ Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands.

PMID: 25921419
DOI: 10.1016/j.critrevonc.2015.04.004

Abstract

Purpose: Several studies have shown the potential benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients. At present the most effective chemotherapeutic regime in HIPEC for gastric cancer is unknown. The aim of this review was to provide a comprehensive overview of chemotherapeutic agents used for HIPEC in gastric cancer.

Methods: A literature search was conducted using the PubMed database to identify studies on chemotherapy used for HIPEC in gastric cancer patients.

Results and conclusion: The chemotherapeutic regime of choice in HIPEC for gastric cancer has yet to be determined. The wide variety in studies and study parameters, such as chemotherapeutic agents, dosage, patient characteristics, temperature of perfusate, duration of perfusion, carrier solutions, intraperitoneal pressure and open or closed perfusion techniques, warrant more experimental and clinical studies to determine the optimal treatment schedule. A combination of drugs probably results in a more effective treatment.

Keywords: Chemotherapy; Hyperthermia; Intraoperative period; Intraperitoneal; Metastasis; Peritoneal neoplasms; Pharmacokinetics; Stomach neoplasms.

Publication types

Review

MeSH terms

Antineoplastic Agents / administration & dosage*
Chemotherapy, Cancer, Regional Perfusion*
Humans
Hyperthermia, Induced*
Peritoneal Neoplasms / drug therapy*
Peritoneal Neoplasms / secondary*
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / pathology

Substances

Antineoplastic Agents